Adaptive Biotechnologies Beheer
Beheer criteriumcontroles 2/4
De CEO Adaptive Biotechnologies is Chad Robins, benoemd in Sep2009, heeft een ambtstermijn van 15.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.90M, bestaande uit 7.4% salaris en 92.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.23% van de aandelen van het bedrijf, ter waarde $ 8.51M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.2 jaar en 8.8 jaar.
Belangrijke informatie
Chad Robins
Algemeen directeur
US$8.9m
Totale compensatie
| Percentage CEO-salaris | 7.4% |
| Dienstverband CEO | 15.2yrs |
| Eigendom CEO | 1.2% |
| Management gemiddelde ambtstermijn | 6.2yrs |
| Gemiddelde ambtstermijn bestuur | 8.8yrs |
Recente managementupdates
Recent updates
Adaptive Biotechnologies: Making Some Progress
Nov 26Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce
Nov 26
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$195m |
| Jun 30 2024 | n/a | n/a | -US$213m |
| Mar 31 2024 | n/a | n/a | -US$215m |
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$423k | -US$46m |
Compensatie versus markt: De totale vergoeding ($USD 8.90M ) Chad } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.18M ).
Compensatie versus inkomsten: De vergoeding van Chad is gestegen terwijl het bedrijf verliesgevend is.
CEO
Chad Robins (50 yo)
15.2yrs
Tenure
US$8,904,267
Compensatie
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 8.5m | |
| President & COO | 6.8yrs | US$2.97m | 0.32% $ 2.2m | |
| Co-Founder & Chief Scientific Officer | 15.2yrs | US$8.61m | 0.69% $ 4.8m | |
| Chief Commercial Officer of Immune Medicine | 6.8yrs | US$2.88m | 0.22% $ 1.5m | |
| Founder | no data | geen gegevens | geen gegevens | |
| VP, CFO & Principal Accounting Officer | 3.1yrs | US$1.66m | 0.10% $ 723.8k | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief People Officer | 5.6yrs | geen gegevens | 0.17% $ 1.2m | |
| Chief Commercial Officer of MRD | 4.3yrs | geen gegevens | 0.17% $ 1.2m | |
| Senior Vice President of MRD BioPharma | 1.2yrs | geen gegevens | geen gegevens |
6.2yrs
Gemiddelde duur
50yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ADPT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 8.5m | |
| Lead Independent Director | 10.9yrs | US$355.00k | 0.093% $ 647.1k | |
| Member of Corporate Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.7yrs | US$330.00k | 0.035% $ 243.6k | |
| Independent Director | 11.8yrs | US$325.00k | 0.051% $ 356.3k | |
| Independent Director | 6.8yrs | US$310.00k | 0.037% $ 254.6k | |
| Member of Corporate Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Corporate Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Corporate Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Corporate Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 3.7yrs | US$310.00k | 0.038% $ 263.2k |
8.8yrs
Gemiddelde duur
58.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ADPT wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).